Concerning DKD, a case control study of patients enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial demonstrated that baseline serum FGF23 levels did not predict the CKD incidence in 590 T2D patients [36]. The gene discussed is FGF23; the disease is diabetes mellitus.